SAMHSA Issues Landmark Advisory Expanding Pharmacist Authority to Prescribe Buprenorphine

The Substance Abuse and Mental Health Services Administration has issued a comprehensive advisory that could fundamentally reshape how Americans access medication for opioid use disorder. Released on June 22, the document outlines an expanded role for pharmacists in prescribing buprenorphine—a move that public health advocates say could bridge critical gaps in treatment access, particularly in rural and underserved communities.

The advisory arrives at a pivotal moment. Despite sustained national progress in reducing overdose deaths—down 14% for the third consecutive year—an estimated 1.8 million Americans with opioid use disorder remain without treatment. Geographic barriers, provider shortages, and bureaucratic hurdles have long prevented many from accessing buprenorphine, one of three FDA-approved medications for opioid addiction and widely considered the most accessible due to its monthly pickup schedule at retail pharmacies.

From Collaborative Agreements to Independent Authority

The path to pharmacist prescribing authority has been gradual. Following the 2022 Mainstreaming Addiction Treatment Act, which eliminated the X-waiver requirement and allowed more providers to prescribe buprenorphine, attention turned to state-level scope-of-practice laws that continued to restrict pharmacist independence. Some pharmacists gained limited prescribing ability through collaborative practice agreements with licensed physicians, but these arrangements were available only in select states and often required complex administrative frameworks.

The landscape shifted in late 2025 when the SUPPORT Act reauthorization authorized DEA-licensed pharmacists to prescribe buprenorphine independently after completing an eight-hour training specific to the medication. However, implementation remained uneven. To date, only California and Idaho have established full pathways for independent pharmacist prescribing of buprenorphine, leaving millions of Americans in other states without this expanded access point.

SAMHSA's new advisory does not create binding policy, but it provides federal cover for states considering similar expansions. The document emphasizes that "a pharmacist's ability to prescribe and dispense MOUD is especially important for communities that have limited access to or awareness of OUD treatment." It notes that pharmacists often serve as the first point of contact in the care continuum and typically maintain longer hours than traditional medical providers—factors that make them uniquely positioned to provide streamlined, low-barrier access to treatment.

A Harm Reduction-Compatible Framework

Perhaps most notably, the advisory adopts language that aligns with harm reduction principles at a time when the agency has been shifting toward more abstinence-oriented messaging. While recent SAMHSA communications have emphasized tapering off medication-assisted treatment, this document presents long-term maintenance as a legitimate clinical option, noting that "clinical experience shows that some patients may require long-term treatment with medications."

The advisory also addresses practical concerns that have historically deterred pharmacists from engaging with buprenorphine prescribing. On the sensitive topic of medication diversion—when prescribed medication is used by someone other than the intended patient—SAMHSA urges a nuanced approach. "Medication diversion is a complex topic and is often misunderstood," the document states, advising pharmacists not to automatically decline prescriptions they find questionable without first consulting both the patient and prescriber. The advisory notes that buprenorphine is rarely associated with fatal overdose on its own, and when deaths do occur, other substances are almost always present.

For patients who use multiple substances, the advisory takes an explicitly pragmatic stance. "In the context of the overdose crisis, it is safer to initiate MOUD without requiring abstinence from multiple substances." This represents a significant departure from traditional abstinence-based approaches that often required patients to stop using all drugs before beginning medication-assisted treatment—a requirement that research has shown creates dangerous delays and drives many away from care entirely.

Urine Testing and Patient Dignity

The document also revisits the contentious practice of urine drug screening, which has become standard in many opioid treatment programs despite limited evidence of benefit. SAMHSA's advisory acknowledges that urine testing "may be useful for assisting with treatment adherence" but emphasizes that in isolation, the practice "has limited utility and effect on patient outcomes" and "may be viewed as punitive by patients."

This framing represents a subtle but meaningful shift toward patient-centered care. Rather than treating suspicion as the default posture, the advisory encourages pharmacists to consider the therapeutic relationship and the potential for drug screening to undermine trust. The message aligns with growing recognition in addiction medicine that punitive approaches often backfire, driving patients away from protective medical oversight and toward more dangerous unregulated drug use.

The State-by-State Patchwork

Despite the federal advisory, significant barriers remain. Pharmacist prescribing authority continues to vary dramatically by state, creating a patchwork of access that leaves many Americans without this expanded care option. As of early 2026, only ten states allowed pharmacist prescribing of controlled medications for opioid use disorder in any form, and only two had implemented the independent prescribing pathway authorized by the SUPPORT Act.

This state-level variation reflects broader tensions in American healthcare federalism. While the federal government can authorize new scopes of practice through legislation like the SUPPORT Act, implementation depends on state boards of pharmacy and legislatures, many of which remain cautious about expanding controlled substance prescribing authority. The SAMHSA advisory provides political cover and clinical guidance for states considering expansion, but it cannot compel action.

Implications for Treatment Access

The potential impact of expanded pharmacist prescribing is substantial. There are approximately 88,000 retail pharmacies in the United States, compared to roughly 1,800 opioid treatment programs and a limited number of physicians waivered to prescribe buprenorphine. Pharmacies are geographically distributed more evenly than specialized addiction treatment providers, with many communities lacking any dedicated substance use disorder clinic but maintaining at least one retail pharmacy.

For rural areas, where provider shortages and geographic isolation create severe treatment barriers, pharmacist prescribing could be transformative. The advisory specifically highlights these communities, noting that pharmacies often represent the only healthcare access point within reasonable distance. Extended operating hours—many pharmacies remain open evenings and weekends when physician offices are closed—could further reduce barriers for working patients who struggle to attend daytime medical appointments.

The advisory also addresses the intersection of medication-assisted treatment and telehealth services, noting that pharmacists can play a crucial role in supporting patients receiving care through virtual platforms. As telehealth flexibilities for controlled substance prescribing remain extended through December 2026, the combination of remote physician oversight and local pharmacist dispensing could create new care models that blend accessibility with clinical oversight.

Looking Forward

SAMHSA's advisory arrives amid broader uncertainty about federal addiction policy direction. The agency has recently sent mixed signals about medication-assisted treatment, with some communications emphasizing long-term maintenance while others have promoted tapering and abstinence-based recovery. The pharmacist advisory appears to fall on the side of expanded access and harm reduction, though its non-binding nature limits its immediate impact.

For the millions of Americans with opioid use disorder who remain untreated, the document offers a potential path forward—one that leverages existing healthcare infrastructure rather than requiring massive new investments in specialized treatment capacity. Whether states will act on this federal guidance remains to be seen, but the advisory adds momentum to a growing recognition that addressing the overdose crisis will require deploying every available tool, including the pharmacists who already serve their communities every day.

As the nation continues its third consecutive year of declining overdose deaths, innovations in treatment access could help sustain and accelerate this progress. The SAMHSA advisory represents one such innovation—an attempt to meet patients where they are, in the pharmacies they already visit, with the medications that could save their lives.